Gebel, S.; Müller, T.
Keystone Symposia NF-KAPPA B Regulation And Function: From Basic Research To Drug Development 2000
Studies on stress signal transduction in swiss 3T3 cells exposed to aqueous extracts of CS (‘smoke-bubbled PBS’) revealed the activation of mitogen activated protein kinases (mapks), i.e., stress-activated protein kinase (SAPK) and p38, as well as the modulation of transcription factors AP-1 and NF-kappa B as detected by electromobility shift assay techniques. Unlike complexes, that bind to AP-1 sites, NF-kappa B DNA binding was strikingly decreased during the first 2 h of exposure followed by a more than 2- fold increase over controls after 4 to 6 h of exposure. This type of kinetics is not subject to regulation by i kappa b-alpha has evidenced by the lack of phosphorylation and degradation of i kappa b-alpha in CS-treated cells.However, as demonstrated by immuno-co-precipitation experiments, the kinetics of NF-kappa B DNA-binding was strictly paralleled by decreased and increased complex formation between NF-kappa B and thioredoxin (TRX), the reducing catalyst of cys-62 of NF-kappa B, which is required for efficient DNA binding. These results suggest that the activity of NF-kappa B in smoke-bubbled PBS-treated cells is subject mainly to a redoxcontrolled mechanism dependent on the availability of reduced TRX rather than being controlled by its normal regulator I Kappa B-Alpha.
PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization.
Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.